2 weeks Ago By ABMN Staff
Mizuho began coverage on shares of Tectonic Therapeutic ( NASDAQ:TECX – Free Report ) in a research note released on Monday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $51.00 price objective on the stock.
Separately, Wells Fargo & Company reduced their price target on Tectonic Therapeutic from $112.00 to $101.00 and set an “overweight” rating on the stock in a research report on Friday, March 21st.
Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $72.40.
Get Our Latest Research Report on TECX Tectonic Therapeutic Price Performance Tectonic Therapeutic ( NASDAQ:TECX – Get Free Report ) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.
39) by $0.55. As a group, equities research analysts anticipate that Tectonic Therapeutic will post -8.
31 earnings per share for the current fiscal year. Insider Activity In other Tectonic Therapeutic news, Director Timothy A. Springer acquired 3,718 shares of the firm’s stock in a transaction on Wednesday, April 9th.
The stock was acquired at an average cost of $14.76 per share, for a total transaction of $54,877.68.
Following the purchase, the director now owns 4,317,276 shares in the company, valued at approximately $63,722,993.76. The trade was a 0.
09 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, CFO Daniel Lochner acquired 4,617 shares of the business’s stock in a transaction dated Wednesday, February 5th.
The stock was acquired at an average price of $54.14 per share, for a total transaction of $249,964.38.
Following the purchase, the chief financial officer now directly owns 4,617 shares of the company’s stock, valued at approximately $249,964.38. This trade represents a ∞ increase in their ownership of the stock.
The disclosure for this purchase can be found here . Insiders have purchased 234,607 shares of company stock valued at $8,955,655 over the last ninety days. 9.
20% of the stock is currently owned by insiders. Hedge Funds Weigh In On Tectonic Therapeutic A number of institutional investors have recently modified their holdings of TECX. Geode Capital Management LLC boosted its stake in shares of Tectonic Therapeutic by 147.
7% in the third quarter. Geode Capital Management LLC now owns 76,879 shares of the company’s stock worth $2,331,000 after buying an additional 45,846 shares during the last quarter. Exome Asset Management LLC lifted its holdings in Tectonic Therapeutic by 12.
2% in the third quarter. Exome Asset Management LLC now owns 36,344 shares of the company’s stock valued at $1,101,000 after acquiring an additional 3,955 shares during the period. Clarius Group LLC purchased a new stake in Tectonic Therapeutic in the 4th quarter worth approximately $468,000.
China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tectonic Therapeutic during the 4th quarter worth approximately $144,000.
Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Tectonic Therapeutic during the 4th quarter valued at approximately $218,000. Hedge funds and other institutional investors own 62.
63% of the company’s stock. Tectonic Therapeutic Company Profile ( Get Free Report ) Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A.
Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. Featured Articles Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter .
.
